Cancer Therapy News and Research

RSS

Cytogen Corporation and Dowpharma collaborate to create a targeted oncology product designed to treat prostate and other cancers

Under the agreement, Dowpharma's proprietary MeO-DOTA bifunctional chelant technology will be used to radiolabel Cytogen's prostate-specific membrane antigen (PSMA) antibody with a therapeutic radionuclide. PSMA is a protein highly expressed on the surface of prostate cancer cells and the neovasculature of many solid tumors.

10 May 2005

Researchers develop promising new gene network analysis method

Compared with a long-used linear model, a correlation-based statistical method is a more reliable way to map complex gene interactions and pinpoint genes that may be potential cancer treatment targets, according to new Brown University research.

8 May 2005

Promising new molecular targets and treatment approaches for some of the most malignant brain tumors

The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. Researchers found that a little-known protein called Fra-1 was effective in controlling vascular endothelial growth factor D, a factor that promotes the growth of new blood vessels in most malignant brain tumors.

8 May 2005

Fusing physics with medicine to fight cancer

Everyone’s lives are touched by cancer - it is a disease that affects 1 in 3 of us throughout our lifetime. Future developments that lead to earlier diagnosis and more effective therapy lie in further successful collaboration between high energy physicists and the healthcare industry.

2 May 2005

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Researchers at Vanderbilt University Medical Center in a new report say that blocking the COX-1 enzyme - not COX-2 - might lead to a way to prevent and treat the most common and fatal form of ovarian cancer.

2 May 2005

Cancer treatment - timing is everything

Research led by a cancer biologist at The Cleveland Clinic Lerner Research Institute has identified a molecular mechanism that links the body's internal clock to daily variations in how a patient responds to cancer treatment.

28 Apr 2005

Black cohosh may interfere with breast cancer drugs

Black cohosh, an herb widely used by breast cancer patients to alleviate hot flashes and other menopausal symptoms, may alter the way that cells respond to drugs commonly used to treat breast cancer, according to a Yale School of Medicine study in Breast Cancer Research and Treatment.

27 Apr 2005

National clinical trial examines new option for kidney cancer patients

The trial, which opened last September, offers research subjects who qualify a new, targeted therapy in addition to standard immune therapy. The drug combination is being studied in a national Phase II clinical trial led by OHSU Cancer Institute researcher Christopher Ryan, M.D., through the Southwest Oncology Group, one of the largest clinical trial cooperative groups in the United States.

27 Apr 2005

Herceptin in combination with chemotherapy reduces risk of breast cancer recurrence in women with with early-stage breast cancer

Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.

26 Apr 2005

Herceptin provides hope to new breast cancer sufferers

According to new research, Herceptin, Genentech's breast cancer treatment has shown promise in treating the early stages of breast cancer.

25 Apr 2005

Elderly lung cancer patients tolerate combined chemotherapy and radiotherapy with no higher risk of death than younger patients

Lung cancer remains the leading cause of cancer deaths in the U.S., with half of those diagnosed at age 70 years or older. About 20 percent of patients with lung cancer will have small cell lung cancer (SCLC). In the past, SCLC progressed rapidly despite initial chemotherapy sensitivity and few patients survive three years.

25 Apr 2005

Smad7 protein levels may predict prostate cancer therapy response

Levels of the Smad7 protein may predict therapeutic response in patients with prostate cancer according to research published by investigators at the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR).

23 Apr 2005

Scientists have, for the first time, induced a state of reversible metabolic hibernation in mice

Scientists at Fred Hutchinson Cancer Research Center have, for the first time, induced a state of reversible metabolic hibernation in mice. This achievement, the first demonstration of "hibernation on demand" in a mammal, ultimately could lead to new ways to treat cancer and prevent injury and death from insufficient blood supply to organs and tissues.

23 Apr 2005

Using light under your skin

You have a tiny wound on your hand that doesn’t heal, a bad burn on your chest – or an injured retina. Your doctor cannot tell how serious the injuries are below the surface. He needs tissue samples. That means using a scalpel, which again equals pain, perhaps even a risk. Soon there may be hope for an improved and totally harmless method to peer under the surface of the skin: light.

23 Apr 2005

Mice put into "suspended animation" in U.S.

Researchers from the University of Washington and the Fred Hutchinson Cancer Research Centre in Seattle have placed mice in a state of near suspended animation, raising the possibility that in future hibernation could be induced in humans.

22 Apr 2005

Cancer patients may one day benefit from treatment with mixtures of customized antibodies

In a study published recently in the Proceedings of the National Academy of Sciences (USA), a team of Weizmann Institute scientists have demonstrated how the right combination might form a web that destroys the cancer cell's communication network, ultimately demobilizing the cell.

22 Apr 2005

Clinical study of MDX-010/MDX-1379 combination shows durable responses in patients with metastatic melanoma

Medarex, Inc. and Bristol-Myers Squibb Company announced today that complete or partial responses in seven of 56 patients with metastatic melanoma showed durability ranging from four months to the longest still ongoing at over 34 months, with five of the seven responses ongoing for more than two years.

20 Apr 2005

Reducing expression of a gene called BRCC36 makes breast cancer cells more responsive to ionizing radiation

The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research (AACR) in Anaheim, Calif. BRCC36 directly interacts with the BRCA1 protein. Almost all invasive breast cancer cells have elevated BRCC36 levels compared to normal breast milk-duct cells.

20 Apr 2005

Selenium will have critical role in prostate cancer treatment

Researchers at Fox Chase Cancer Center in Philadelphia have come a step closer to understanding selenium's molecular role in causing prostate cancer cells to self-destruct. According to data presented today at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, Calif., selenium helps malignant cells overcome their resistance to TRAIL-induced apopstosis (self-inflicted cell death).

20 Apr 2005

New drug, RAD001, shown to stop the growth of ovarian cancer cells

A new drug, RAD001, has been shown to stop the growth and movement of certain ovarian cancer cells, according to scientists at Fox Chase Cancer Center in Philadelphia. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research (AACR) in Anaheim, Calif.

20 Apr 2005

Cancer Therapy News and Research

Cytogen Corporation and Dowpharma collaborate to create a targeted oncology product designed to treat prostate and other cancers

Researchers develop promising new gene network analysis method

Promising new molecular targets and treatment approaches for some of the most malignant brain tumors

Fusing physics with medicine to fight cancer

Blocking the COX-1 enzyme might be the answer in ovarian cancer treatment

Cancer treatment - timing is everything

Black cohosh may interfere with breast cancer drugs

National clinical trial examines new option for kidney cancer patients

Herceptin in combination with chemotherapy reduces risk of breast cancer recurrence in women with with early-stage breast cancer

Herceptin provides hope to new breast cancer sufferers

Elderly lung cancer patients tolerate combined chemotherapy and radiotherapy with no higher risk of death than younger patients

Smad7 protein levels may predict prostate cancer therapy response

Scientists have, for the first time, induced a state of reversible metabolic hibernation in mice

Using light under your skin

Mice put into "suspended animation" in U.S.

Cancer patients may one day benefit from treatment with mixtures of customized antibodies

Clinical study of MDX-010/MDX-1379 combination shows durable responses in patients with metastatic melanoma

Reducing expression of a gene called BRCC36 makes breast cancer cells more responsive to ionizing radiation

Selenium will have critical role in prostate cancer treatment

New drug, RAD001, shown to stop the growth of ovarian cancer cells

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News